covid-19 information patient

Trial shows Covid-19 patients recover with Gilead’s remdesivir

Reading now: 849
www.pharmaceutical-technology.com

Preliminary data from a clinical trial led by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) showed that Gilead Sciences’ remdesivir exhibited faster recovery in Covid-19 patients.

The ACTT trial, involving 1063 hospitalised patients with advanced Covid-19 and lung involvement, compared the experimental antiviral drug to placebo.

An interim analysis by the independent data and safety monitoring board (DSMB) found that remdesivir performed better on the primary endpoint of ‘time to recovery’  when compared to placebo.

Results showed a 31% faster time to recovery in patients treated with Gilead’s drug versus placebo. The median time to recovery was 11 days versus 15 days, respectively.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA